

Hiroshi Yokouchi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/461358/publications.pdf>

Version: 2024-02-01

21
papers

387
citations

840728

11
h-index

839512

18
g-index

21
all docs

21
docs citations

21
times ranked

722
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic significance of OX40 ⁺ lymphocytes in tumor stroma of surgically resected small-cell lung cancer. <i>Oncolmunology</i> , 2021, 10, 1971430.	4.6	2
2	Delta-like 1 homolog (DLK1) as a possible therapeutic target and its application to radioimmunotherapy using 125I-labelled anti-DLK1 antibody in lung cancer models (HOT1801 and FIGHT004). <i>Lung Cancer</i> , 2021, 153, 134-142.	2.0	10
3	Detection of somatic TP53 mutation in surgically resected small-cell lung cancer by targeted exome sequencing: association with longer relapse-free survival. <i>Heliyon</i> , 2020, 6, e04439.	3.2	7
4	A prospective phase II study of carboplatin and nab-paclitaxel in patients with advanced non-small cell lung cancer and concomitant interstitial lung disease (HOT1302). <i>Lung Cancer</i> , 2019, 138, 65-71.	2.0	32
5	A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101). <i>International Journal of Clinical Oncology</i> , 2018, 23, 1060-1069.	2.2	0
6	Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin in patients with chemo-naïve extensive-stage small-cell lung cancer: North Japan Lung Cancer Study Group (NJLCG) 0901. <i>Lung Cancer</i> , 2017, 111, 38-42.	2.0	8
7	A retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 615-622.	2.3	13
8	Rikkunshito for Preventing Chemotherapy-Induced Nausea and Vomiting in Lung Cancer Patients: Results from 2 Prospective, Randomized Phase 2 Trials. <i>Frontiers in Pharmacology</i> , 2017, 8, 972.	3.5	12
9	Immunohistochemical profiling of receptor tyrosine kinases, MED12, and TGF- β RII of surgically resected small cell lung cancer, and the potential of c-kit as a prognostic marker. <i>Oncotarget</i> , 2017, 8, 39711-39726.	1.8	13
10	Expression of Notch1 and Numb in small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 10348-10358.	1.8	22
11	A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 (PEOPLE Study). <i>Respiratory Research</i> , 2016, 17, 90.	3.6	93
12	A phase II trial of erlotinib monotherapy for pretreated elderly patients with advanced EGFR wild-type non-small cell lung cancer. <i>BMC Research Notes</i> , 2015, 8, 220.	1.4	6
13	Prognostic impact of clinical variables on surgically resected small-cell lung cancer: Results of a retrospective multicenter analysis (FIGHT002A and HOT1301A). <i>Lung Cancer</i> , 2015, 90, 548-553.	2.0	16
14	Revisiting the role of COX-2 inhibitor for non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2015, 4, 660-4.	2.8	21
15	Phase II trial of carboplatin and pemetrexed as first-line chemotherapy for non-squamous non-small cell lung cancer, and correlation between the efficacy/toxicity and genetic polymorphisms associated with pemetrexed metabolism: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0902. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 1149-1157.	2.3	11
16	Cyclooxygenase-2 inhibitors for non-small-cell lung cancer: A phase II trial and literature review. <i>Molecular and Clinical Oncology</i> , 2014, 2, 744-750.	1.0	14
17	Clinical and molecular profiling of surgically resected small-cell lung cancer: Intergroup study with FIGHT002 and HOT1301.. <i>Journal of Clinical Oncology</i> , 2014, 32, 7590-7590.	1.6	0
18	Randomized phase 2 study of carboplatin plus irinotecan (CI) versus carboplatin plus amrubicin (CA) for extensive disease small-cell lung cancer (ED-SCLC): NJLCG0901.. <i>Journal of Clinical Oncology</i> , 2014, 32, 7521-7521.	1.6	0

#	ARTICLE	IF	CITATIONS
19	Anti- α 40 monoclonal antibody therapy in combination with radiotherapy results in therapeutic antitumor immunity to murine lung cancer. <i>Cancer Science</i> , 2008, 99, 361-367.	3.9	83
20	Combination tumor immunotherapy with radiotherapy and Th1 cell therapy against murine lung carcinoma. <i>Clinical and Experimental Metastasis</i> , 2007, 24, 533-540.	3.3	9
21	Tetramer-blocking assay for defining antigen-specific cytotoxic T lymphocytes using peptide-MHC tetramer. <i>Cancer Science</i> , 2006, 97, 148-154.	3.9	15